Anxiolytics, sedatives, and older patients

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Newer antidepressants, such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and other dual-action compounds (eg, mirtazapine), are currently considered the first-line treatment for several anxiety disorders and mixed anxiety/depression syndromes in younger patients. Although anxiety syndromes as a group are the most common psychiatric conditions in late life, controlled trials of anxiolytics in older patients are relatively sparse. While the controlled trials of these newer agents in the elderly are expected to be conducted over the next decade, clinical experience of geriatric psychiatrists suggests similar efficacy of these compounds in late-life anxiety syndromes. Because of their favorable adverse-effect profiles, the newer antidepressants seem to be much better tolerated by older people than many of the anxiolytic medications used in the past. Short-acting benzodiazepines can be useful adjuncts or alternative treatment strategies in selected circumstances.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalPrimary Psychiatry
Volume11
Issue number8
Publication statusPublished - Aug 2004
Externally publishedYes

Fingerprint

Anti-Anxiety Agents
Hypnotics and Sedatives
Anxiety
Antidepressive Agents
Psychiatry
Serotonin Uptake Inhibitors
Anxiety Disorders
Benzodiazepines
Geriatrics
Depression
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • Psychiatry and Mental health

Cite this

Anxiolytics, sedatives, and older patients. / Sheikh, Javaid.

In: Primary Psychiatry, Vol. 11, No. 8, 08.2004, p. 51-54.

Research output: Contribution to journalReview article

@article{f950837c51c241758e88f8fdd3fd5ec7,
title = "Anxiolytics, sedatives, and older patients",
abstract = "Newer antidepressants, such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and other dual-action compounds (eg, mirtazapine), are currently considered the first-line treatment for several anxiety disorders and mixed anxiety/depression syndromes in younger patients. Although anxiety syndromes as a group are the most common psychiatric conditions in late life, controlled trials of anxiolytics in older patients are relatively sparse. While the controlled trials of these newer agents in the elderly are expected to be conducted over the next decade, clinical experience of geriatric psychiatrists suggests similar efficacy of these compounds in late-life anxiety syndromes. Because of their favorable adverse-effect profiles, the newer antidepressants seem to be much better tolerated by older people than many of the anxiolytic medications used in the past. Short-acting benzodiazepines can be useful adjuncts or alternative treatment strategies in selected circumstances.",
author = "Javaid Sheikh",
year = "2004",
month = "8",
language = "English",
volume = "11",
pages = "51--54",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "8",

}

TY - JOUR

T1 - Anxiolytics, sedatives, and older patients

AU - Sheikh, Javaid

PY - 2004/8

Y1 - 2004/8

N2 - Newer antidepressants, such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and other dual-action compounds (eg, mirtazapine), are currently considered the first-line treatment for several anxiety disorders and mixed anxiety/depression syndromes in younger patients. Although anxiety syndromes as a group are the most common psychiatric conditions in late life, controlled trials of anxiolytics in older patients are relatively sparse. While the controlled trials of these newer agents in the elderly are expected to be conducted over the next decade, clinical experience of geriatric psychiatrists suggests similar efficacy of these compounds in late-life anxiety syndromes. Because of their favorable adverse-effect profiles, the newer antidepressants seem to be much better tolerated by older people than many of the anxiolytic medications used in the past. Short-acting benzodiazepines can be useful adjuncts or alternative treatment strategies in selected circumstances.

AB - Newer antidepressants, such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and other dual-action compounds (eg, mirtazapine), are currently considered the first-line treatment for several anxiety disorders and mixed anxiety/depression syndromes in younger patients. Although anxiety syndromes as a group are the most common psychiatric conditions in late life, controlled trials of anxiolytics in older patients are relatively sparse. While the controlled trials of these newer agents in the elderly are expected to be conducted over the next decade, clinical experience of geriatric psychiatrists suggests similar efficacy of these compounds in late-life anxiety syndromes. Because of their favorable adverse-effect profiles, the newer antidepressants seem to be much better tolerated by older people than many of the anxiolytic medications used in the past. Short-acting benzodiazepines can be useful adjuncts or alternative treatment strategies in selected circumstances.

UR - http://www.scopus.com/inward/record.url?scp=4344703034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344703034&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 51

EP - 54

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 8

ER -